Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Prof Hendrik Swart richly contributes to research of phosphors
2014-12-02

Prof Hendrik Swart
Photo: Merwelene van der Merwe

Since his appointment as the South African Research Chairs Initiative (SARChI) Chair, there has been a sharp increase in the number of papers and publications by Prof Hendrik Swart, Senior Professor in the Department of Physics at the University of the Free State (UFS). From January this year, he has already published 78 articles. Some of the journals that has published his work, includes:

• Nanotechnology (impact of 3.67)
• Dalton Transactions (impact of 4.097)
• Sensors and Actuators B: Chemical (impact 3.84)

“My biggest success, however, is the powerful group of researchers we have built over the years. Staff, postdocs and students – without them it would have been impossible. I am therefore much indebted to my groups on both the Bloemfontein and Qwaqwa Campuses.

“The good apparatus we acquired via a sponsorship from the National Research Foundation and Sasol is also one of the main reasons for this. The financial support I get from the university’s research office is of course also a contributing factor,” he says.

For the past 20 years, Prof Swart has been conducting research on any substance that glows. “I only adjust the focus to fit in with current trends,” he says.

Prof Swart believes that his research will make a contribution to the fundamental knowledge about phosphors, as well as to the training of good students for the academic and industrial world on the outside. For the man on the street, his research translates into better, brighter lights that use less energy.

His more recent research focuses on the development of nano-phosphors for light-emitting diodes (LEDS) and organic light-emitting diodes (OLED).

Prof Swart has presented papers on his research not only nationally, but all over the world – including countries in Europe and the East. Some of the most recent papers presented by him and his colleagues/postgraduate students include:

• Applications of AES, XPS and TOF SIMS to phosphor materials at die 15th European Conference on Applications of Surface and Interface Analysis 2013 in Forte Village Resort, Sardinia, Italy.
• Luminescent properties of phosphor nano thin films at the first International Symposium on Nanoparticles/Nanomaterials and Applications in Caparica (Lisbon, Portugal), where he was an invited speaker.
• Role of surface and deep-level defects on the emission of nano metal oxides at the 2014 NanoAfrica international conference, Vanderbijlpark, South Africa, where he delivered the keynote address.
• PHI systems and their modifications at KOVSIES at the PHI European User Meeting in Ismaning (Munich), Germany, where he was invited to speak.

Prof Swart also delivered the keynote address at the SETCOR International Conference on Smart Materials and Surfaces in Bangkok, Thailand. His lecture was titled, ‘Role of surface and deep-level defects on the emission and degradation of phosphor materials’.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept